Catalent Appoints David McErlane as Biologics Segment Leader
18 Setembro 2023 - 6:00PM
Business Wire
Catalent, Inc. (NYSE: CTLT), the leader in enabling the
development and supply of better treatments for patients worldwide,
today announced that David McErlane has been named Group President
of Catalent’s Biologics segment, effective September 25, 2023.
Mr. McErlane joins Catalent from Lonza, where he served as
senior vice president and business unit head for Lonza’s Bioscience
business. Prior to joining Lonza, Mr. McErlane held several
leadership positions at MilliporeSigma and BioReliance after
beginning his career as an engineering manager at Zeneca. He holds
a bachelor’s degree in electronic systems engineering from Glasgow
Caledonian University.
“David is a seasoned and highly successful business leader with
a record of developing winning strategies that drive growth and
create significant value,” said Alessandro Maselli, President and
Chief Executive Officer of Catalent. “I am excited to work with
David, who I am confident will make an immediate, positive impact
on our Biologics business and help take Catalent to its next phase
of growth.”
Mr. McErlane will lead all of Catalent’s Biologics businesses
and global service offerings – including development, drug
substance manufacturing, drug product fill-and-finish, cell and
gene therapy, and analytical services.
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT), is the global leader in enabling
pharma, biotech, and consumer health partners to optimize product
development, launch, and full life-cycle supply for patients around
the world. With broad and deep scale and expertise in development
sciences, delivery technologies, and multi-modality manufacturing,
Catalent is a preferred industry partner for personalized
medicines, consumer health brand extensions, and blockbuster drugs.
Catalent helps accelerate over 1,500 partner programs and launch
over 150 new products every year. Its flexible manufacturing
platforms at over 50 global sites supply approximately 70 billion
doses of nearly 8,000 products annually. Catalent’s expert
workforce of nearly 18,000 includes more than 3,000 scientists and
technicians. Headquartered in Somerset, New Jersey, the company
generated nearly $4.3 billion in revenue in its 2023 fiscal year.
For more information, visit www.catalent.com.
More products. Better treatments. Reliably supplied.™
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230918343681/en/
Investor Contact: Paul Surdez (732) 537-6325
investors@catalent.com Media Contact: Bernie Clark +1 (732)
537-6400 media@catalent.com
Catalent (NYSE:CTLT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Catalent (NYSE:CTLT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024